Nkarta (NKTX) Non Operating Income (2019 - 2026)
Nkarta (NKTX) posted quarterly Non Operating Income of $3.0 million for Q1 2026, down 33.55% year-over-year from $4.6 million in Q1 2025, and down 14.3% quarter-over-quarter from $3.6 million in Q4 2025.
Nkarta (NKTX) Non Operating Income (2019 - 2026) Analysis & Trends
Nkarta's Non Operating Income history runs 8 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 33.55% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $16.4 million (down 21.05% YoY), while the FY2025 annual figure was $17.9 million, down 7.68% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.0 million, down from $3.6 million in the prior quarter.
- The five-year high for Non Operating Income was $5.7 million in Q2 2024, with the low at $111000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $3.6 million (2025), against an average of $3.5 million.
- The sharpest annual moves came in 2022 and 2026: Non Operating Income surged 3189.04% in 2022, then slumped 33.55% in 2026.
- Nkarta's Non Operating Income stood at $2.4 million in 2022, then soared by 42.9% to $3.4 million in 2023, then soared by 45.38% to $5.0 million in 2024, then decreased by 28.79% to $3.6 million in 2025, then declined by 14.3% to $3.0 million in 2026.
- Business Quant data shows NKTX's Non Operating Income at $3.0 million in Q1 2026, $3.6 million in Q4 2025, and $5.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 2.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.76 Mn |
| Mar 31, 2026 | 3.04 Mn |
| Dec 31, 2025 | 3.55 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 4.58 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Sep 30, 2024 | 5.45 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 3.43 Mn |
| Sep 30, 2023 | 3.65 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 3.50 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 1.92 Mn |
| Jun 30, 2022 | 689,000.00 |
| Mar 31, 2022 | 111,000.00 |
| Dec 31, 2021 | 73,000.00 |
| Sep 30, 2021 | 75,000.00 |